Non‑Small Cell Lung Cancer | Emerging Role of Antibody‑Drug Conjugates in the Management of Non‑Small Cell Lung Cancer
Research To Practice | Oncology Videos · Dr. Neil Love
December 16, 202259m 1s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Featuring perspectives from Drs Alexander Spira and Helena Yu, including the following topics:
- Introduction
- What is an antibody-drug conjugate? (0:00)
- "HER2-Positive" Non-Small Cell Lung Cancer (NSCLC)
- Case: A woman in her mid 50s with HER2 insertion in exon 20 — Dr Yu (8:42)
- Targeting HER3 in NSCLC
- Case: A man in his early 60s with lung cancer with an EGFR mutation — Dr Yu (25:23)
- TROP2-Directed Treatment
- Case: A woman in her early 50s with lung cancer with a KRAS G12V mutation — Dr Spira (36:57)
- Case: A woman in her mid 60s with metastatic NSCLC and an EGFR exon 19 deletion — Dr Spira (39:32)
- Novel Agents
- Mechanism of action of tusamitamab ravtansine and telisotuzumab vedotin (54:15)